Literature DB >> 28421399

Effect of intravitreal aflibercept (Eylea®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration.

Mustafa Gok1, Hasan Burhanettin Kapti2.   

Abstract

PURPOSE: To investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients with neovascular age-related macular degeneration (nAMD).
METHODS: Twenty eyes of 20 patients with nAMD scheduled for single intravitreal aflibercept (Eylea®) injection and 20 fellow eyes (uninjected) were enrolled in this prospective interventional study. The hemodynamic parameters of the ophthalmic artery (OA), central retinal artery (CRA) and posterior ciliary artery (PCA) comprising peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) were measured by using color Doppler ultrasonography (CDU) in both injected and uninjected fellow eyes at baseline and 1 week after the injection.
RESULTS: The measured first-week values of PSV and EDV in the CRA, OA and PCA showed a statistically significant reduction when comparing baseline values in both injected and uninjected fellow eyes (p = 0.0001). Also, it was found a significant increase in the post-injection RI values of all the CRA, OA, PCA in injected eye and OA in the uninjected eye (p = 0.0001). There was any significant difference between pre- and post-injection RI values of the CRA and PCA in the fellow eyes (p = 0.137, p = 0.736, respectively).
CONCLUSION: Single intravitreal administration of aflibercept alters retrobulbar blood flow velocities (BFVs) in both injected and uninjected fellow eyes in the short-term period.

Entities:  

Keywords:  Aflibercept; Age-related macular degeneration; Color Doppler ultrasonography; Retrobulbar blood flow

Mesh:

Substances:

Year:  2017        PMID: 28421399     DOI: 10.1007/s10792-017-0522-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  34 in total

Review 1.  The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.

Authors:  Hiroyuki Takahashi; Masabumi Shibuya
Journal:  Clin Sci (Lond)       Date:  2005-09       Impact factor: 6.124

2.  Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.

Authors:  Claus Zehetner; Martina T Kralinger; Yasha S Modi; Inga Waltl; Hanno Ulmer; Rudolf Kirchmair; Nikolaos E Bechrakis; Gerhard F Kieselbach
Journal:  Acta Ophthalmol       Date:  2014-12-08       Impact factor: 3.761

3.  Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration.

Authors:  Ahmet Mete; Oguzhan Saygili; Alper Mete; Metin Bayram; Necdet Bekir
Journal:  J Clin Ultrasound       Date:  2010-02       Impact factor: 0.910

4.  Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.

Authors:  Efstratios Mendrinos; Georgios Mangioris; Domniki N Papadopoulou; Guy Donati; Constantin J Pournaras
Journal:  Acta Ophthalmol       Date:  2013-05       Impact factor: 3.761

5.  Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.

Authors:  Izumi Yoshida; Tomoaki Shiba; Hikari Taniguchi; Mao Takahashi; Takeyoshi Murano; Nobuyuki Hiruta; Yuichi Hori; Hdieaki Bujo; Takatoshi Maeno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-17       Impact factor: 3.117

6.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

7.  Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.

Authors:  Xiying Wang; Tomoko Sawada; Osamu Sawada; Yoshitsugu Saishin; Ping Liu; Masahito Ohji
Journal:  Am J Ophthalmol       Date:  2014-06-25       Impact factor: 5.258

8.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

9.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

10.  Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Authors:  Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante Joseph Pieramici; Robert See; Stephen Couvillion; Ma'an A Nasir; Melvin D Rabena; Kha Le; Mauricio Maia; Jennifer E Visich
Journal:  Br J Ophthalmol       Date:  2014-07-07       Impact factor: 4.638

View more
  1 in total

1.  Short-term effect on the ocular circulation induced by unilateral intravitreal injection of aflibercept in age-related maculopathy.

Authors:  Anna Sophie Mursch-Edlmayr; Nikolaus Luft; Dominika Podkowinski; Michael Ring; Leopold Schmetterer; Matthias Bolz
Journal:  Acta Ophthalmol       Date:  2019-03-27       Impact factor: 3.761

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.